DBT
Dược phẩm Bến Tre ·HOSE ·2026Q1
▲▲ Improving positively
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, DBT has not accelerated revenue sharply, but profitability is improving visibly — earnings have been recovering gradually over multiple periods. However, a significant portion of profit is supported by non-core sources, making the picture not entirely clear.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 190.0 | 279.0 | 177.0 | 243.2 | 161.2 | 258.4 | 200.6 | 224.1 | 185.4 | 246.1 | 189.2 | 202.7 |
| Growth | -32% | +58% | -27% | +51% | -38% | +29% | -11% | +21% | -25% | +30% | -7% | — |
| Net Income | 15.3 | 3.2 | 0.6 | 9.6 | 2.0 | 4.6 | 0.6 | 1.4 | 6.1 | 7.2 | 0.6 | -1.5 |
| Net Margin | 8.06% | 1.14% | 0.34% | 3.93% | 1.27% | 1.77% | 0.28% | 0.62% | 3.29% | 2.91% | 0.33% | -0.76% |
Drivers of DBT's profit
Net profit attributable to parent increased vs last year, mainly helped by higher financial income. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by higher financial income. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE rose from 3.1% to 9.7% — mainly driven by asset turnover, despite leverage moving in the opposite direction.
Is the profit sustainable?
Margins improved (+2.2pp), but earnings still rely significantly on non-core sources — warrants closer scrutiny.
What is driving the margin?
Net margin expanded to 3.22%, rising 2.2pp. Core operating signals are improving as SG&A / Revenue fell 2.1pp are enough to offset pressure from Gross margin fell 2.8pp (with additional support from Net financial result / Revenue rose 2.0pp and Other profit / Revenue rose 1.6pp).
Most of the margin increase comes from non-core items — core operations have not kept pace, this is a margin expansion to watch carefully.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Watchpoints
Financial result accounts for 37.5% of PBT and lifted net margin by 3.6pp — separate the operating contribution from this source.
Is capital being used efficiently?
Return on capital rose, but cash cycle lengthened by 11.1 days — working capital needs watching.
Is capital being deployed efficiently?
ROIC edged up to 2.11%, rising 1.1pp. That translates to 2.11 in after-tax operating profit for every 100 units of operating capital. The main driver is NOPAT margin rose 1.1pp, with capital turnover broadly stable; with invested capital holding roughly steady.
NOPAT margin led the improvement, but the ROIC level has not yet cleared typical cost of capital — margin needs to hold in coming periods rather than being a one-period rebound.
Watchpoints
ROIC is currently 2.11% — below the typical cost-of-capital threshold; worth tracking whether upcoming periods can rise above this level.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC is improving — the asset structure below shows how capital is being allocated. Leverage is elevated, requiring monitoring — liabilities at 2.40x equity, net debt at 1.76x equity.
Inventory ended the period at 424.9bn, roughly 42.9% of total assets.
Over the last 12 months, working capital absorbed 2.2bn of cash, mainly because of higher receivables and lower payables. Part of that drag was offset by lower inventories.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
The inventory build-up noted above is reflected in a longer cash cycle. Cash conversion cycle lengthened by 11.1 days versus the same period last year. The main moves came from DIO fell 5.7 days, DSO rose 2.0 days, and DPO fell 14.8 days.
Working capital cycle lengthened mainly due to shorter payment timing — may reflect pressure from suppliers.
Watchpoints
CCC stands at 319.7 days, suggesting that working capital remains tied up for a relatively long operating cycle.
DSO increased by +2.0 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
High leverage combined with negative operating cash flow — this area needs close monitoring.
Leverage & Liquidity
Leverage warrants monitoring, with net debt / equity at 1.76x and interest coverage only at 0.58x.
At present, short-term debt accounts for 97.8% of total debt, cash equals 1.4% of debt, and total debt stands at 543.4bn.
Watchpoints
Net debt / equity stands at 1.76x, increasing balance-sheet pressure.
Interest coverage is 0.58x, leaving limited room to absorb financing costs.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
High leverage combined with cash flow below reveals the actual liquidity pressure. Operating cash flow reached -10.9bn in 2025, against investing cash flow of 20.2bn.
Post-investment cash flow was positive +9.4bn. Financing cash flow was positive +3.6bn.
CFO / net income was 2.19x.
After spending +2.6bn on fixed-asset investment, the business generated trailing free cash flow of +61.0bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is operating efficiency, with net margin improving 2.2 pp. The next item to monitor is the earnings mix, when non-core contribution is -48.7%. The main risk still sits in capital efficiency remains weak, with ROIC at 2.1%.
Improvement: operating efficiency is getting better, with trailing-12M net margin at 3.22% after expanding 2.2pp versus the same period last year.
Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 2.19x. Even so, net financial result still accounts for -48.7% of PBT, so the earnings mix still needs monitoring.
Key risk: Capital efficiency remains weak.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
|
Net Revenue
|
860.3 | 868.4 | 811.6 | 754.6 | 611.2 |
|
Cost of Goods Sold
|
521.9 | 522.3 | 502.0 | 503.4 | 0.0 |
|
Gross Profit
|
338.4 | 346.1 | 309.6 | 251.2 | 183.5 |
|
Financial Expenses
|
43.0 | 40.7 | 49.7 | 27.6 | -24.7 |
|
Selling Expenses
|
229.9 | 236.8 | 192.2 | 162.0 | -137.1 |
|
General and Administrative Expenses
|
63.5 | 60.1 | 50.3 | 53.0 | -36.6 |
|
Operating Profit
|
8.9 | 16.9 | 22.9 | 19.2 | 21.4 |
|
Profit Before Tax
|
24.0 | 20.4 | 23.1 | 50.9 | 21.8 |
|
Net Income
|
14.4 | 12.3 | 17.5 | 40.5 | 17.3 |
|
Profit Attributable to Parent
|
14.2 | 14.6 | 16.2 | 38.0 | 18.1 |
|
Earnings per Share
|
614.00 | 772.00 | 893.00 | 2,261.00 | 1,273.25 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.